Cosentyx is a monoclonal antibody treatment option for several conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and others. Following the initial loading dose, subcutaneous injection of Cosentyx is required every four weeks, but patients can typically be taught to self-administer using the Sensoready pen or prefilled syringe. Nasopharyngitis and an elevated risk of infection are the most frequently reported side effects.
Cosentyx is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondylarthritis, and Enthesitis-related Arthritis.
Skyrizi, an interleukin inhibitor, is prescribed to alleviate inflammation associated with plaque psoriasis, psoriatic arthritis, or Crohn's disease in adults. The recommended dose is 150mg administered every 12 weeks as two subcutaneous injections of 75mg, which patients can learn to self-administer. The most frequently reported side effects are upper respiratory tract infections, headache, and fatigue.
Skyrizi is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, and Crohnâ€™s Disease.